Sub menu

 
 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

1062 result(s) found, displaying 151 to 175

  • AusPAR: Xpovio

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Xpovio (selinexor) for treatment of relapsed or refractory multiple myeloma

  • AusPAR: Ponvory

    Australian Public Assessment Report (AusPAR)
    For the treatment of adult patients with relapsing forms of multiple sclerosis

  • AusPAR: Kimmtrak

    Australian Public Assessment Report (AusPAR)
    For the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

  • AusPAR: Rybelsus

    Australian Public Assessment Report (AusPAR)
    Rybelsus (semaglutide) has been approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

  • AusPar: Spikevax

    Australian Public Assessment Report (AusPAR)
    AusPAR for SPIKEVAX COVID-19 VACCINE (elasomeran) as booster in 12 to 17 years of age for prevention of COVID-19

  • AusPAR: Yuflyma

    Australian Public Assessment Report (AusPAR)
    AusPAR for Yuflyma (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis etc.

  • AusPAR: Cosentyx

    Australian Public Assessment Report (AusPAR)
    AusPAR for Cosentyx (secukinumab) for the treatment of plaque psoriasis, psoriatic arthritis and axial spondyloarthritis etc.

  • Isturisa

    Australian Public Assessment Report (AusPAR)
    AusPAR for Isturisa (osilodrostat as phosphate) for the treatment of endogenous Cushing’s syndrome in adults.

  • AusPAR: Dazalex SC

    Australian Public Assessment Report (AusPAR)
    AusPAR for DARZALEX SC (daratumumab) for the treatment of light chain AL amyloidosis

  • AusPAR: Vaxneuvance

    Australian Public Assessment Report (AusPAR)
    AusPAR for Vaxneuvance (pneumococcal 15-valent conjugate vaccine (CRM197 protein), adsorbed) for the prevention of pneumococcal disease.

  • AusPAR: Sogroya

    Australian Public Assessment Report (AusPAR)
    AusPAR for SOGROYA (somapacitan) indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency.

  • AusPAR: Tozinameran

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Comirnaty (tozinameran) for the prevention of COVID-19 in individuals 6 months of age and older.

  • AusPAR: Libtayo

    Australian Public Assessment Report (AusPAR)
    AusPAR for LIBTAYO (cemiplimab) for treatment of adult patients with locally advanced and metastatic basal cell carcinoma.

  • AusPAR: Comirnaty

    Australian Public Assessment Report (AusPAR)
    AusPAR for COMIRNATY (tozinameran) for the prevention of COVID-19.

  • AusPAR: Lutetium (177Lu) chloride

    Australian Public Assessment Report (AusPAR)
    AusPAR for Lutetium (177Lu) chloride (lutetium (177Lu) chloride) for the treatment of non-resectable or metastatic neuroendocrine tumours expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.

  • AusPAR: Zeposia

    Australian Public Assessment Report (AusPAR)
    AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.

  • AusPAR: Libtayo

    Australian Public Assessment Report (AusPAR)
    New AusPAR for LIBTAYO (cemiplimab) as first-line treatment of adult patients with non-small cell lung cancer.

  • AusPAR: Pegcetacoplan

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Empaveli (pegcetacoplan) for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria.

  • AusPAR: Tepmetko

    Australian Public Assessment Report (AusPAR)
    Tepmetko (tepotinib) for treatment of non-small cell lung cancer with MET exon 14 skipping alterations.

  • AusPAR: Tecentriq

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.

  • AusPAR: Brukinsa

    Australian Public Assessment Report (AusPAR)
    Brukinsa (zanubrutinib) for the treatment of of adult patients with Waldenström’s macroglobulinaemia

  • AusPAR: Brukinsa

    Australian Public Assessment Report (AusPAR)
    Brukinsa (zanubrutinib) for the treatment of adult patients with mantle cell lymphoma

  • AusPAR: Nextstellis

    Australian Public Assessment Report (AusPAR)
    Nextstellis (estetrol monohydrate and drospirenone) for the prevention of pregnancy

Help us improve the Therapeutic Goods Administration site